Advertisement

Glucocorticoid-Induced Osteoporosis

  • Robert S. Weinstein
Article
bone marrow cells bone formation apoptosis osteoblasts osteocytes osteoclasts remodeling 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 1932;50:137-195.Google Scholar
  2. 2.
    Fitzpatrick LA. Glucocorticoid-induced osteoporosis. In: Osteoporosis. R. Marcus, ed. Boston, MA. Blackwell, 1994:202-226.Google Scholar
  3. 3.
    Reid IR. Pathogenesis and treatment of steroid osteoporosis. Clin Endocrinol 1989;30:83-103.Google Scholar
  4. 4.
    LoCascio V, Bonucci E, Imbimbo B, Ballanti P, Adami S, Milani S, Tartarotti D, DellaRocca C. Bone loss in response to long-term glucocorticoid therapy. Bone Miner 1990;8:39-51.Google Scholar
  5. 5.
    Lukert BP, Kream BE. Clinical and basic aspects of glucocorticoid action in bone. In: Principles of Bone Biology. JP Bilezikian, LG Raisz, GA Rodan, eds. San Diego, CA: Academic Press, 1996:533-548.Google Scholar
  6. 6.
    Mankin HF. Nontraumatic necrosis of bone (osteonecrosis). N Engl J Med 1992;326:1473-1479.Google Scholar
  7. 7.
    Reid IR. Preventing glucocorticoid-induced osteoporosis. N Engl J Med 1997;327:420-421.Google Scholar
  8. 8.
    Hahn TJ, Halstead LR, Baran DT. Effects of short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man. J Clin Endocrinol Metab 1981;52:111-115.Google Scholar
  9. 9.
    Paz-Pacheco E, Fuleihan GE-H, Leboff MS. Intact parathyroid hormone levels are not elevated in glucocorticoid-treated subjects. J Bone Miner Res 1995;10:1713-1718.Google Scholar
  10. 10.
    Prummel MF, Wiersinga WM, Lips P, Sanders GTB, Sauerwein HP. The course of biochemical parameters of bone turnover during treatment with corticosteroids. J Clin Endocrinol Metab 1991;72:382-386.Google Scholar
  11. 11.
    Pearce G, Tabensky DA, Delmas PD, Baker HWG, Seeman E. Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab 1998;83:801-806.Google Scholar
  12. 12.
    Bressot C, Meunier PJ, Chapuy MC, Lejeune E, Edouard C, Darby AJ. Histomorphometric profile, pathophysiology and reversibility of corticosteroid-induced osteoporosis. Metab Bone Dis & Rel Res 1979;1:303-311.Google Scholar
  13. 13.
    Dempster DW, Arlot MA, Meunier PJ. Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis. Calcif Tissue Int 1983;35:410-417.Google Scholar
  14. 14.
    Dempster DW. A prospective: Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 1989;4:137-141.Google Scholar
  15. 15.
    Jowell PS, Epstein S, Fallon MD, Reinhardt A, Ismail F. 1,25-dihydroxyvitamin D3 modulates glucocorticoid-induced alteration in serum bone GLA protein and bone histomorphometry. Endocrinology 1987;120:531-536.Google Scholar
  16. 16.
    Jilka RL, Weinstein RS, Bellido T, Parfitt AM, Manolagas SC. Osteoblast programd cell death (apoptosis): Modulation by growth factors and cytokines. J Bone Miner Res 1998;13:793-802.Google Scholar
  17. 17.
    Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: Potential mechanisms of the deleterious effects on bone. J Clin Invest. 1998;102:274-282.Google Scholar
  18. 18.
    Jilka RL, Weinstein RS, Takahashi K, Parfitt AM, Manolagas SC. Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence. J Clin Invest 1996;97:1732-1740.Google Scholar
  19. 19.
    Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with PTH. J Clin Invest 1999;104:439-446.Google Scholar
  20. 20.
    Manolagas SC, Weinstein RS. Perspective: new developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 1999;14:1061-1066.Google Scholar
  21. 21.
    Weinstein RS, Manolagas SC. Apoptosis and osteoporosis. Am J Med 2000;108:153-164.Google Scholar
  22. 22.
    Vidal NOA, Brändström H, Jonsson KB, Ohlsson C. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: Down-regulation by glucocorticoids. J Endocrinol 1998;159:191-195.Google Scholar
  23. 23.
    Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliot R, Colombero A, Sullivan J, Hawkins N, Davey E, Capparelli C, Eli A, Qian Y-X, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165-176.Google Scholar
  24. 24.
    Weinstein RS, Nicholas RW, Manolagas SC. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab 2000;85:2907-2912.Google Scholar
  25. 25.
    Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocrin Rev 1995;16:3-34.Google Scholar
  26. 26.
    Lecka-Czernik B, Gubrij I, Moerman EJ, Kajkenova O, Lipschitz DA, Manolagas SC, Jilka RL. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARγ2. J Cell Biochem 1999;74:357-371.Google Scholar
  27. 27.
    Chang DJ, Ji C, Kin KK, Casinghino S, McCarthy TL, Centerlla M. Reduction in transforming growth factor beta receptor I expression and transcription factor Cbfa1 on bone cells by glucocorticoids. J Biol Chem 1998;273:4892-4896.Google Scholar
  28. 28.
    Shi XM, Chang ZJ, Blair HC, McDonald JM, Cao X. Glucocorticoids induce adipogenesis of stromal cells by transcriptionally activating PPARγ 2. J Bone Miner Res 1998;12.Google Scholar
  29. 29.
    Bellido T, Han L, Mocharla H, Said S, O'Brien C, Jilka RL, Manolagas SC. Overexpression of Bcl-2 renders osteoblastic cells refractory to glucocorticoid-induced apoptosis. Bone 1998;23:S324.Google Scholar
  30. 30.
    Villareal DT, Civitelli R, Gennari C, Avioli LV. Is there an effective treatment for glucocorticoid-induced osteoporosis? Calcif Tissue Int 1991;49:141-142.Google Scholar
  31. 31.
    Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste.-Marie LG, Tenenhouse A, Chines AA. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:382-387.Google Scholar
  32. 32.
    Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339:292-299.Google Scholar
  33. 33.
    Reid IR, Alexander CJ, King AR, Ibbertson HK. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD). Lancet 1988;I:143-146.Google Scholar
  34. 34.
    Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocrine Rev 1993;14:690-709.Google Scholar
  35. 35.
    Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud C. Parathyroid hormone treatment can reverse glucocorticoid-induced osteoporosis. J Clin Invest 1998;102:1627-1633.Google Scholar
  36. 36.
    Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC. Bellido. Prevention of osteocyte and osteoblast apoptosis by bisphos-phonates and calcitonin. J Clin Invest 1999;184:1363-1374.Google Scholar
  37. 37.
    Baron R, Vignery A, Lang R. Reversal phase and osteopenia: defective coupling of resorption to formation in the pathogenesis of osteoporosis. In: Osteoporosis. DeLuca KF, Frost HM, Jee WSS, Johnston CC, Parfitt AM eds. Baltimore, OH: University Park Press, 1981;311-320.Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • Robert S. Weinstein
    • 1
  1. 1.Department of Internal Medicine, Division of Endocrinology/Metabolism, the Center for Osteoporosis and Metabolic Bone Diseases, and the Central Arkansas Veterans Healthcare SystemUniversity of Arkansas for Medical SciencesLittle Rock

Personalised recommendations